Neprilysin has become a focus of interest in cardiology [1], due to the impressive benefits of combining neprilysin inhibition and angiotensin receptor blockade demonstrated in the PARADIGM-HF trial in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) (HFrEF) [2]. Here, MME is linked to heart failure.